WIRE — Mylan held a 5.64% stake in Biocon as of June 2026, and the transaction marks the complete sale of its holding in the biotechnology company.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.